Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) General Counsel Jeff Cislini sold 1,500 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $30.99, for a total value of $46,485.00. Following the transaction, the general counsel now owns 54,374 shares in the company, valued at $1,685,050.26. The sale was disclosed in a document filed with the SEC, which is available at this link.
Jeff Cislini also recently made the following trade(s):
- On Monday, March 18th, Jeff Cislini sold 1,252 shares of Revolution Medicines stock. The shares were sold at an average price of $31.58, for a total value of $39,538.16.
- On Monday, January 22nd, Jeff Cislini sold 1,500 shares of Revolution Medicines stock. The shares were sold at an average price of $27.00, for a total value of $40,500.00.
Revolution Medicines Stock Performance
Shares of RVMD opened at $32.23 on Friday. The business has a 50-day moving average of $30.02 and a 200 day moving average of $27.19. Revolution Medicines, Inc. has a fifty-two week low of $15.44 and a fifty-two week high of $35.60. The firm has a market cap of $5.31 billion, a P/E ratio of -8.55 and a beta of 1.53.
Analysts Set New Price Targets
RVMD has been the subject of several research analyst reports. UBS Group initiated coverage on Revolution Medicines in a research report on Wednesday, December 20th. They set a “buy” rating and a $40.00 target price for the company. Wedbush raised their target price on Revolution Medicines from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Raymond James raised their target price on Revolution Medicines from $30.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, January 16th. Bank of America raised Revolution Medicines from a “neutral” rating to a “buy” rating and raised their target price for the company from $31.00 to $34.00 in a research report on Friday, January 5th. Finally, Piper Sandler initiated coverage on Revolution Medicines in a research report on Monday, March 11th. They set an “overweight” rating and a $43.00 target price for the company. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines currently has an average rating of “Buy” and an average target price of $38.80.
View Our Latest Analysis on Revolution Medicines
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in RVMD. Point72 Hong Kong Ltd purchased a new position in Revolution Medicines during the 2nd quarter valued at about $39,000. US Bancorp DE grew its holdings in Revolution Medicines by 68.1% during the 2nd quarter. US Bancorp DE now owns 1,575 shares of the company’s stock valued at $42,000 after buying an additional 638 shares in the last quarter. Shell Asset Management Co. purchased a new position in Revolution Medicines during the 4th quarter valued at about $54,000. KBC Group NV purchased a new position in Revolution Medicines during the 4th quarter valued at about $65,000. Finally, Tower Research Capital LLC TRC grew its holdings in Revolution Medicines by 76.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,418 shares of the company’s stock valued at $74,000 after buying an additional 1,481 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.
About Revolution Medicines
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Featured Stories
- Five stocks we like better than Revolution Medicines
- What Are the FAANG Stocks and Are They Good Investments?
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What is a Death Cross in Stocks?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Choose Top Rated Stocks
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.